Haemonetics AI Stock Analysis
Haemonetics (HAZ) AI Stock Analysis
Haemonetics
(Frankfurt:HAZ)
No summary available
Haemonetics (HAZ) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 5.47B
- Dividend Yield
- ―
- Average Volume (3M)
- 12
- Price to Earnings (P/E)
- 52.9
- Beta (1Y)
- -0.06
- Revenue Growth
- -1.20%
- EPS Growth
- -37.57%
- Country
- Germany
- Employees
- 3,009
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Haemonetics Business Overview & Revenue Model
Company Description
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automat...
Haemonetics Earnings Call Summary
The call was strongly positive overall. The company reported double-digit organic growth in several areas, raised full-year revenue guidance, expanded its CSL relationship, advanced multiple product launches and regulatory approvals, and generated substantial cash flow. The main challenges were lower expected operating margin expansion, higher operating expenses and ramp-related costs, modest weakness in other apheresis, and uncertainty around second-half plasma collection volumes. Management nevertheless expressed confidence in the long-term growth runway and future operating leverage.
Q2-2027 Updates
Positive Updates
Negative Updates
Company Guidance
For fiscal 2027, Haemonetics reaffirmed MedSurg organic revenue growth guidance of mid-single digits and raised apheresis organic revenue growth guidance to high single digits from low to mid-single digits; total company organic growth guidance increased to 6%-9% from 4%-7%, and reported growth guidance to 8%-11% from 5%-8%. The company now expects adjusted operating margin expansion of 0-50 basis points, compared with 50-100 basis points previously, and adjusted earnings per diluted share growth in line with its increased reported revenue growth guidance of 8%-11%. Free cash flow conversion is expected to be in excess of 80% of adjusted net income, with second-half growth weighted towards Q4, and guidance does not include any incremental revenue contribution from second-half plasma collections growth.
Haemonetics Risk Analysis
Haemonetics disclosed 38 risk factors in its most recent earnings report. Haemonetics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksHaemonetics Peers Comparison
Overall Rating
MDT81Outperform
BIO78Outperform
LIVN77Outperform
ABT67Neutral
CERS57Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $128.70B | 24.50 | 10.60% | 2.86% | 9.77% | 12.28% | |
| 78Outperform | $9.93B | 9.40 | 14.07% | ― | 1.38% | ― | |
| 77Outperform | $5.07B | 25.34 | 15.35% | ― | 11.71% | ― | |
| 67Neutral | $179.90B | 38.15 | 9.11% | 2.45% | 10.00% | -66.06% | |
| 57Neutral | $383.71M | -47.68 | -10.54% | ― | 13.74% | 56.08% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:HAZ | Haemonetics | 110.00 | 41.50 | 60.58% | |
| ABT | Abbott Laboratories | 103.00 | -21.11 | -17.01% | |
| BIO | Bio-Rad Laboratories | 358.90 | 36.42 | 11.29% | |
| CERS | Cerus Corporation | 1.85 | 0.16 | 9.47% | |
| MDT | Medtronic | 99.94 | 0.05 | 0.05% | |
| LIVN | LivaNova PLC | 90.73 | 30.27 | 50.07% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
